Core Insights - The stock price of Sinocare Inc. (02591) increased by 5.37%, currently trading at HKD 32.60, with a transaction volume of HKD 33.25 million [1][4] - The first domestically developed ultra-long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing®), has been officially included in the 2025 National Medical Insurance Drug List, effective from January 1, 2026, aimed at controlling blood sugar in adult patients with type 2 diabetes [1][4] - This inclusion marks a significant step towards the accessibility of innovative diabetes treatments in China, aligning with the "Healthy China 2030" initiative [1][4] Industry Developments - The National Guidelines for Diabetes Prevention and Control (2025) have classified Icosapent Ethyl as a GLP-1 receptor agonist injectable, providing direct policy and regulatory support for its use in primary healthcare institutions [1][4] - The guidelines emphasize the importance of GLP-1 receptor agonists as a treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those requiring weight management [1][4]

Group 1 - The stock of Sino Biopharmaceutical Limited (02591.HK) increased by over 3% during trading, reaching a rise of 3.43% at HKD 32 per share [1] - The trading volume amounted to HKD 20.7421 million [1]

Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Yinuo Pharmaceutical-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s product, Icosapent Ethyl, is now recognized as the first domestically developed long-acting GLP-1 receptor agonist in China [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list is aimed at improving the accessibility of innovative diabetes medications [1] - The 2025 National Guidelines for Diabetes Prevention and Management highlight Icosapent Ethyl as a key treatment option for adult patients with type 2 diabetes, especially those with cardiovascular disease risk factors, heart failure, chronic kidney disease, and obesity [1]

消息面上，据银诺医药官微消息，在《"健康中国2030"规划纲要》推动糖尿病防治关口前移、提升创新 药物可及性的战略部署下，中国原研首款超长效人源性GLP-1受体激动剂(GLP-1RA)依苏帕格鲁肽α(商 品名：怡诺轻)正式纳入2025版国家医保药品目录，适用于"成人2型糖尿病患者的血糖控制"，自2026年 1月1日起正式执行。此举标志着我国糖尿病创新治疗普惠化又迈出关键一步。 智通财经APP获悉，银诺医药-B(02591)盘中涨超3%，截至发稿，涨3.43%，报32港元，成交额2074.21 万港元。 在《国家基层糖尿病防治管理指南(2025) 》中，依苏帕格鲁肽ɑ被列为注射类降糖药物的GLP-1RA周制 剂，为基层医疗机构配备和使用该药提供了直接的政策与规范依据。指南强调，对于合并动脉粥样硬化 性心血管疾病(ASCVD)或其风险因素、心力衰竭、慢性肾脏病(CKD)的成人2型糖尿病(T2DM)患者，以 及需要体重管理的超重肥胖患者，GLP-1RA是重要的治疗选择。 ...

每经AI快讯，银诺医药-B(02591.HK)逆市拉升逾23%。截至发稿涨23.38%，报39.44港元，成交额 7649.49万港元。 ...

Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase of over 24% despite a previous decline of more than 25% in the two days following its inclusion in the Stock Connect program, indicating a positive market reaction to recent announcements [1] Group 1: Stock Performance - As of the latest update, the stock price of Silver诺医药-B is reported at 39.44 HKD, reflecting a rise of 23.38% with a trading volume of 76.49 million HKD [1] Group 2: Inclusion in Stock Connect - The company announced that its H shares have been included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025 [1] - The board believes that this inclusion will expand the investor base and increase the trading liquidity of H shares, thereby enhancing the investment value and market reputation of the company [1] Group 3: Product Development - Silver诺医药-B has announced that its self-developed long-acting GLP-1 receptor agonist, Irsuglutide α (怡诺轻), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented from January 1, 2026 [1] - Irsuglutide α (怡诺轻) is characterized by a long half-life, low dosing frequency, and glucose-dependent regulation, making it the third globally and the first in Asia to enter the commercialization stage among long-acting GLP-1 receptor agonists [1] - This product is also noted as the first innovative drug of its kind developed in China, providing high-quality treatment options for type 2 diabetes patients [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase of over 24% despite a previous decline of over 25% in the two days following its inclusion in the Hong Kong Stock Connect program, indicating a positive market reaction to recent announcements [1] Group 1: Stock Performance - As of the latest update, Silver诺医药-B's stock price rose by 23.38%, reaching HKD 39.44, with a trading volume of HKD 76.49 million [1] Group 2: Inclusion in Stock Connect - Silver诺医药-B has been included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025 [1] - The board believes that this inclusion will expand the company's investor base and increase the trading liquidity of its H-shares, thereby enhancing the investment value of H-shares and the company's reputation in the capital market [1] Group 3: Product Development - The company announced that its self-developed long-acting GLP-1 receptor agonist, Irsuglutide α (怡诺轻), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented from January 1, 2026 [1] - Irsuglutide α (怡诺轻) is characterized by a long half-life, low dosing frequency, and blood glucose-dependent regulation, making it the third globally and the first in Asia to enter the commercialization stage among long-acting GLP-1 receptor agonists [1] - This product is also noted as the first innovative drug of its kind developed in China, providing high-quality treatment options for type 2 diabetes patients [1]

Group 1 - The Hang Seng Index fell by 0.84%, down 215 points, closing at 25,549 points, while the Hang Seng Tech Index dropped by 1.32% [1] - The trading volume in the Hong Kong stock market reached HKD 107.8 billion in the morning session [1] - Optical communication stocks surged, driven by increased demand for high-speed optical transceiver modules, with institutions predicting a significant rise in shipment volumes next year [1] Group 2 - Notable gainers included Hongteng Precision, which rose by 7.95%, and Changfei Optical Fiber, which increased by 4.57% [1] - Zhaoyan New Drug saw an increase of over 8% due to a surge in the price of experimental monkeys, with institutions indicating a potential widening supply-demand gap [1] - The stock of Excellence Education, a provider of digital solutions for higher education, rose over 16% on its second day of trading, with its market value approaching HKD 10 billion [1] Group 3 - Oil stocks collectively declined, with geopolitical events weakening support for oil prices, although institutions remain optimistic about the long-term investment value of major oil companies [1] - PetroChina fell by 3%, Sinopec by 2.21%, and CNOOC by 2.32% [1] Group 4 - The non-ferrous metals sector faced significant declines, with Jiangxi Copper down 5.96%, Luoyang Molybdenum down 6.27%, and China Aluminum down 5.34% due to market concerns over central banks' interest rate policies [2] - Silver Noble Pharmaceuticals saw a drop of over 14%, with a cumulative decline of 25% since entering the market [2] Group 5 - Ocean Park Corporation's stock fell by 9%, reaching a new low for the year, amid financial product repayment issues faced by its controlling shareholder [3]

（文章来源：每日经济新闻） 每经AI快讯，银诺医药-B(02591.HK)昨日获纳入港股通后跌超14%，今早继续下挫，累计跌幅达25%。 截至发稿，跌12.73%，报32.9港元，成交额1969.26万港元。 ...

消息面上，上交所、深交所日前发布公告称，因恒生综合中型股指数实施成份股调整，根据有关规定， 港股通标的名单发生调整，将银诺医药调入港股通，自2025年12月8日起生效。此外，银诺医药12月7日 宣布，公司自主研发的超长效GLP-1受体激动剂依苏帕格鲁肽α（怡诺轻 ）正式纳入2025年国家医保药 品目录，将自2026年1月1日起与新版目录同步实施。依苏帕格鲁肽α（怡诺轻 ）是国产超长效GLP-1受 体激动剂。 银诺医药-B(02591)昨日获纳入港股通后跌超14%，今早继续下挫，累计跌幅达25%。截至发稿，跌 12.73%，报32.9港元，成交额1969.26万港元。 ...